BioCentury: Orexo is Dissolving Away Opioid Addiction with New Medication

cancerdrugs-150x150Orexo (ORX.ST) is an emerging specialty pharmaceutical company in route to enter the market with their new medication Zubsolv; an oral medication that dissolves under the tongue to treat opioid addiction. This new medication combines two drugs; buprenorphine and naloxone. Zubsolv is not the first medication of its kind and will be in direct competition with Subutex and Suboxone. Orexo states that the main benefit to their new medication is that less drug is utilized in their dosages compared to their competition to deliver similar relief. About 5 million people in the United States are abusing opioids but only 20% receive treatment. At its peak, Orexo is predicting to have at least $500 million in sales. This new drug is expected to launch in the U.S in September. Trading Volume: 15,636; 12 Month Trail: $33.70-75.50.

View the full article here: (

View the profile page here: (


The comments are closed.